Complete financial analysis of BioXcel Therapeutics, Inc. (BTAI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioXcel Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Trimegah Bangun Persada Tbk (NCKL.JK) Income Statement Analysis – Financial Results
- Tonking New Energy Group Holdings Limited (8326.HK) Income Statement Analysis – Financial Results
- DukSan Neolux Co.,Ltd (213420.KQ) Income Statement Analysis – Financial Results
- Minor International Public Company Limited (MINOF) Income Statement Analysis – Financial Results
- MKS Instruments, Inc. (MKSI) Income Statement Analysis – Financial Results
BioXcel Therapeutics, Inc. (BTAI)
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.38M | 375.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.26M | 20.00K | 297.00K | 188.00K | 156.00K | 17.00K | 1.00K | 0.00 | 0.00 |
| Gross Profit | 120.00K | 355.00K | -297.00K | -188.00K | -156.00K | -17.00K | -1.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 8.70% | 94.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 84.33M | 91.24M | 52.71M | 58.00M | 25.80M | 14.56M | 2.69M | 1.40M | 233.00K |
| General & Administrative | 63.51M | 68.76M | 54.23M | 24.30M | 7.80M | 5.40M | 1.85M | 721.00K | 0.00 |
| Selling & Marketing | 19.90M | 13.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 83.41M | 68.76M | 54.23M | 24.30M | 7.80M | 5.40M | 1.85M | 721.00K | 403.00K |
| Other Expenses | 4.16M | -427.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 171.90M | 160.00M | 106.94M | 82.30M | 33.60M | 19.96M | 4.54M | 2.12M | 636.00K |
| Cost & Expenses | 173.16M | 160.02M | 106.94M | 82.30M | 33.60M | 19.96M | 4.54M | 2.12M | 636.00K |
| Interest Income | 5.65M | 2.53M | 4.00K | 155.00K | 633.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.31M | 8.21M | 40.00K | 27.00K | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 318.00K | 327.00K | 297.00K | 188.00K | 156.00K | 17.00K | 1.00K | 2.12M | 0.00 |
| EBITDA | -165.42M | -157.38M | -107.00M | -81.98M | -32.81M | -19.25M | -4.54M | 0.00 | -636.00K |
| EBITDA Ratio | -11,987.03% | -42,011.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -171.78M | -159.65M | -106.94M | -82.30M | -33.60M | -19.96M | -4.54M | -2.12M | -636.00K |
| Operating Income Ratio | -12,447.97% | -42,572.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.27M | -6.11M | -358.00K | 128.00K | 633.00K | 692.00K | -2.00K | 0.00 | 0.00 |
| Income Before Tax | -179.05M | -165.76M | -106.93M | -82.17M | -32.97M | -19.27M | -4.54M | -2.12M | -636.00K |
| Income Before Tax Ratio | -12,974.86% | -44,201.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 6.09M | -301.00K | -161.00K | -633.00K | 692.00K | 0.00 | -2.12M | 0.00 |
| Net Income | -179.05M | -171.85M | -106.63M | -82.01M | -32.34M | -19.27M | -4.54M | -2.12M | -636.00K |
| Net Income Ratio | -12,974.86% | -45,826.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.15 | -6.13 | -4.04 | -3.78 | -1.99 | -1.32 | -0.30 | -0.14 | -0.04 |
| EPS Diluted | -6.15 | -6.13 | -4.04 | -3.78 | -1.99 | -1.32 | -0.30 | -0.14 | -0.04 |
| Weighted Avg Shares Out | 29.13M | 28.02M | 26.37M | 21.68M | 16.29M | 14.57M | 15.19M | 15.65M | 15.94M |
| Weighted Avg Shares Out (Dil) | 29.13M | 28.02M | 26.37M | 21.68M | 16.29M | 14.57M | 15.19M | 15.65M | 15.94M |
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
BioXcel Therapeutics Announces Proposed Public Offering
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
BioXcel Therapeutics to Present at ThinkEquity Conference
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Source: https://incomestatements.info
Category: Stock Reports